News und Analysen
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: Siltronic AG posts strong results for third quarter of 2022
EQS-News: Siltronic AG posts strong results for third quarter of 2022
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis
EQS-News: Nemetschek SE: Continued Double-Digit Growth in Q3 2022 Driven by High Demand for Subscription and SaaS
EQS-News: Nemetschek SE: Continued Double-Digit Growth in Q3 2022 Driven by High Demand for Subscription and SaaS
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Hannover Medical School to create molecular patient database in autoimmune diseases
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-News: MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
EQS-Adhoc: VARTA AG: Preliminary results for the third quarter and nine-month figures 2022
EQS-Adhoc: VARTA AG: Preliminary results for the third quarter and nine-month figures 2022
EQS-News: Siltronic AG: EIB supports development of Siltronic’s next generation of silicon wafers
EQS-News: Siltronic AG: EIB supports development of Siltronic’s next generation of silicon wafers
EQS-Adhoc: Nagarro SE: Further increase in guidance for FY 2022
EQS-Adhoc: Nagarro SE: Further increase in guidance for FY 2022
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec launches PanOmics data analysis platform PanHunter at Bio-IT World
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: Evotec and TIAP expand LAB150 BRIDGE partnership to include Amgen
EQS-News: United Internet confirms sales forecast and specifies EBITDA forecast for 2022. Lower capex requirement.
EQS-News: United Internet confirms sales forecast and specifies EBITDA forecast for 2022. Lower capex requirement.
EQS-Adhoc: 1&1 Forecast 2022: Revenue target confirmed, earnings increased. Capex needs and customer growth lower.
EQS-Adhoc: 1&1 Forecast 2022: Revenue target confirmed, earnings increased. Capex needs and customer growth lower.
EQS-News: Nagarro Announces Resignation of Vice-Chairperson Detlef Dinsel from Supervisory Board
EQS-News: Nagarro Announces Resignation of Vice-Chairperson Detlef Dinsel from Supervisory Board
EQS-Adhoc: VARTA AG: Herbert Schein resigns as Chairman of the Executive Board with immediate effect, but remains on the Executive Board until 31 December 2022
EQS-Adhoc: VARTA AG: Herbert Schein resigns as Chairman of the Executive Board with immediate effect, but remains on the Executive Board until 31 December 2022
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL
EQS-News: Nagarro refinances its syndicated loan facility
EQS-News: Nagarro refinances its syndicated loan facility
EQS-Adhoc: Nagarro SE: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 10 million Euro
EQS-Adhoc: Nagarro SE: Management Board of Nagarro SE resolves on share buyback program with a volume of up to 10 million Euro
EQS-Adhoc: VARTA AG: VARTA AG withdraws forecast for financial year 2022 and the third quarter of 2022
EQS-Adhoc: VARTA AG: VARTA AG withdraws forecast for financial year 2022 and the third quarter of 2022
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: Just – Evotec Biologics awarded contract from the U.S. Department of Defense under accelerated antibodies program
EQS-News: United Internet AG takes a further step in preparation for a possible IPO of IONOS
EQS-News: United Internet AG takes a further step in preparation for a possible IPO of IONOS
DGAP-News: 1&1 mobile network: Unexpected delay at first stopover due to supply bottlenecks
DGAP-News: 1&1 mobile network: Unexpected delay at first stopover due to supply bottlenecks
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)
DGAP-News: Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse, France (EU)